| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.8M | -67.1% | -66.9% |
| SG&A Expense | $2.6M | +4.2% | -15.3% |
| Operating Income | -$6.4M | +54.4% | +55.9% |
| Net Income | -$4.9M | +26.8% | +50.4% |
| EPS (Basic) | -$0.06 | +45.5% | +76.0% |
| EPS (Diluted) | -$0.06 | +45.5% | +76.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $39.3M | +266.1% | +78.7% |
| Current Assets | $42.9M | +125.1% | +59.8% |
| Total Assets | $43.4M | +121.2% | +57.3% |
| Current Liabilities | $6.7M | -46.2% | -47.6% |
| Total Liabilities | $6.9M | -45.5% | -47.6% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$21.2M | — | — |
| Capital Expenditures | $3K | — | — |
| Investing Cash Flow | -$3K | — | — |
| Financing Cash Flow | $36.0M | — | — |
| Free Cash Flow | -$21.2M | — | — |
| $36.5M |
| +419.7% |
| +152.2% |